Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ.
about
Country-specific HPV-related genital disease among men residing in Brazil, Mexico and The United States: The HIM study.Cutaneous beta human papillomaviruses and the development of male external genital lesions: A case-control study nested within the HIM Study.Genital Human Papillomavirus Infection Progression to External Genital Lesions: The HIM Study.Cutaneous human papillomavirus types detected on the surface of male external genital lesions: a case series within the HPV Infection in Men Study.A case of erythroplasia of queyrat treated with imiquimod 5% cream and excision.Anogenital malignancies and pre-malignancies.Topics in penile dermatology.2013 European guideline for the management of balanoposthitis.Recent advances in the prevention and treatment of skin cancer using photodynamic therapy.Oncogenic human papillomavirus DNA loads in human immunodeficiency virus-positive women with high-grade cervical lesions are strongly elevated.Diagnosis and management of premalignant penile lesions.Human papillomavirus associated with oesophageal cancer.Squamous cell carcinoma in situ of the skin: history, presentation, biology and treatment.Absence of human papillomavirus in tonsillar squamous cell carcinomas from Chinese patientsSeroprevalence of Cutaneous Human Papillomaviruses and the Risk of External Genital Lesions in Men: A Nested Case-Control Study.Genital HPV infection and related lesions in menEpigenetic mechanisms in penile carcinoma.Human papillomavirus infection and p16 expression in the immunocompetent patients with extragenital/extraungual Bowen's disease.Human papillomavirus infection: etiopathogenesis, molecular biology and clinical manifestations.The treatment of penile carcinoma in situ (CIS) within a UK supra-regional network.Seroprevalence of cutaneous human papillomaviruses (HPVs) among men in the multinational HPV Infection in Men study.Erythroplasia of queyrat.Comparison of the Natural History of Genital HPV Infection among Men by Country: Brazil, Mexico, and the United States.Prevalence and Risk of Penile Human Papillomavirus Infection: Evidence From The National Health and Nutrition Examination Survey 2013-2014.Functional similarity between E6 proteins of cutaneous human papillomaviruses and the adenovirus E1A tumor-restraining module.P16(INK4A) immunostaining is a strong indicator for high-risk-HPV-associated oropharyngeal carcinomas and dysplasias, but is unreliable to predict low-risk-HPV-infection in head and neck papillomas and laryngeal dysplasias.Erythroplasia of Queyrat treated with topical 5-fluorouracil.Detection of human papilloma virus in normal skin and in superficial and nodular basal cell carcinomas in immunocompetent subjects.Rapid onset of multifocal human papillomavirus 72-associated oral intraepithelial neoplasia in a human immunodeficiency virus-infected patient.Topical cidofovir for erythroplasia of Queyrat of the glans penis.Treatment of Bowen's disease and erythroplasia of Queyrat.Methylaminolaevulinic acid photodynamic therapy in the treatment of erythroplasia of Queyrat.Erythroplasia of Queyrat with Zoon's balanitis: a diagnostic dilemma.Bowen's disease involving the urethra.The impact of cidofovir treatment on viral loads in adult recurrent respiratory papillomatosis.Human papillomavirus-negative ileostomal chronic papillomatous dermatitis.
P2860
Q30275666-3EDDF4FB-0FCA-44AD-96FF-30E031BDDB62Q30276138-DD2CD495-CDD6-4B5A-A85E-3B3F18085751Q30279220-F390C852-2FBE-47C3-B3BB-12301EBD63DFQ30409315-5CF74E94-0DD0-4A20-9885-FBEC384A0A34Q33817068-FCF081FC-97CC-4CD9-86F4-100F15936EBDQ34161073-895CD3F0-C11B-4150-9F0F-DD5A49DA1845Q34419091-AB8F24B3-3412-4010-9511-845E7129CB07Q34420017-80F910CB-0300-4CEA-BD37-4E1164004E9FQ34537216-BE09D819-E35A-430A-86E0-CFBA23BDA480Q35026841-90276937-30E2-4E2D-B464-4A15E8657FCAQ35174499-B13CD86B-8615-4888-A1F9-3CE8069B1CF0Q35586298-454C63B9-9C6F-4D36-82BE-B3800025B11EQ35666541-0F519A56-E8E7-4A8D-A0A5-62EC6F7AB4DBQ35843271-FB7FC6DF-F086-42C1-9338-E1809C8283B0Q36205731-A1153572-C039-4864-B790-809FC21E5C4BQ36389950-2977D74B-B65C-4D64-BF15-652C511844E0Q37007058-5F9EA346-EEF5-49B1-909F-299FAE49BFD2Q37035380-9BC31EC2-37C1-44C6-BCC9-38FF0923A4FCQ37878367-7CD86D00-6CB0-4D1E-A154-23841E62B1D7Q38233752-34820DAF-5589-4925-93FD-BAF34231B50EQ38377027-0CFA8D2A-94D5-4F4B-A7FC-C3075BB78426Q38679813-1B68EC75-3CC0-4127-99EE-FA93315C4667Q40226418-E35D4BC9-60B7-4CAB-B6B8-85591C11FDBFQ40330382-19B300B3-0AD5-406D-BD40-3D9B6A38F619Q42214281-6FEABF7D-8618-4991-9A21-7EE08D800905Q42262395-1A1D1F13-CF7E-42B7-A33B-4F961D3F29CBQ42319994-80613575-80F6-4334-986D-4B1A89CB51CEQ42479511-D14096B9-2F17-4E08-92E4-80FDE8C9C06DQ43493610-CC0959D6-02E2-4FE8-B81D-7CF9428FB358Q44099090-E55781CB-2CDC-46B6-9798-36F784A1CF72Q44654963-CB122FE5-8442-4D26-A40E-2B1FBC7282AFQ46304243-90132381-7FB1-453D-90C5-3EB232A285E2Q50766537-BFBD0F4A-58FB-4564-94C8-434339A7BDD8Q50767515-9D420477-EE1B-4634-B6A1-15F0D82369D6Q54302139-69D621B3-3219-4254-9967-3668613C128FQ54779325-408A9841-0DDD-4C83-9E71-C7FE6635F129
P2860
Erythroplasia of queyrat: coinfection with cutaneous carcinogenic human papillomavirus type 8 and genital papillomaviruses in a carcinoma in situ.
description
2000 nî lūn-bûn
@nan
2000 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@ast
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@en
type
label
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@ast
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@en
prefLabel
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@ast
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@en
P2093
P1476
Erythroplasia of queyrat: coin ...... iruses in a carcinoma in situ.
@en
P2093
P304
P356
10.1046/J.1523-1747.2000.00069.X
P407
P577
2000-09-01T00:00:00Z
P5875
P6179
1029220371